Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

A Phasei/Iia Clinical Study Of Cetuximab Combined With Fruquintinib In The Third-Line Treatment Of Ras/Braf Wild-Type Colorectal Cancer.

Yong Li,Yan-chun Qu,Yufeng Liu,Yi-hong Liu,Yan-juan Zhu,Yongsong Ye,Xian Chen,Xin Qu,Li-rong Liu,Wenzhu Li,Fangfang Hou,Haibo Zhang

JOURNAL OF CLINICAL ONCOLOGY（2021）

Cited 0|Views9
No score
Abstract
TPS151Background: The standard third-line treatment of mCRC is regofenib, fruquintinib or TAS-102. However, the efficacy was not satisfied. Because VEGF and EGFR share the downstream signal pathway...
More
Translated text
Key words
colorectal cancer,cetuximab,fruquintinib,third-line,wild-type
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined